Scholarlink

<p>Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab. We perform integrated spatial, transcriptomic, and immune profiling of longitudinal tumor and blood samples from patients treated on the MAYA trial. Post-TMZ increases in tumor mutational burden associate with improved progression-free survival. Spatial profiling demonstrates that clinical benefit is greatest in permissive tumor microenvironments. Responders exhibit enrichment of cytotoxic T cells across tumor and stromal compartments, whereas non-responders display heterogeneous cellular neighborhoods, with fibroblasts in close spatial proximity to T cells, consistent with barriers to immune-mediated clearance. Longitudinal peripheral immune profiling shows that early upregulation of TIGIT and PD-1 following TMZ exposure predicts resistance. Together, these findings indicate that both mutational evolution and spatial immune architecture contribute to immune sensitization in MGMT-silenced MSS CRC. Clinical Trial Identification: NCT03832621.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Joan Choo,
  • Joseph J. Zhao,
  • Mai Chan Lau,
  • Alessandra Raimondi,
  • Willa Wen-You Yim,
  • Sruthi Ranganathan,
  • Kexin Zhu,
  • Crystal Tze Ying Tan,
  • Hui Xian Chin,
  • Chong Boon Teo,
  • Khi Yung Fong,
  • Ryan Yong Kiat Tay,
  • Jia-Ying Joey Lee,
  • Lit-Hsin Loo,
  • Paolo Manca,
  • Federica Morano,
  • Michele Prisciandaro,
  • Giovanni Randon,
  • Camilla Damonte,
  • Elisa Micarelli,
  • Guido Leoni,
  • Elisa Scarselli,
  • Sara Lonardi,
  • Chiara Cremolini,
  • Federica Marmorino,
  • Jeffrey Chun Tatt Lim,
  • Zhen Wei Neo,
  • Felicia Wee,
  • Li Yen Chong,
  • Craig Ryan Joseph,
  • Akhila Balachander,
  • Diana GS Lim,
  • You Yi Hwang,
  • Laurent Renia,
  • Subhra Kumar Biswas,
  • David Tan,
  • Joe P. S. Yeong,
  • Raghav Sundar,
  • Filippo Pietrantonio

摘要

Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab. We perform integrated spatial, transcriptomic, and immune profiling of longitudinal tumor and blood samples from patients treated on the MAYA trial. Post-TMZ increases in tumor mutational burden associate with improved progression-free survival. Spatial profiling demonstrates that clinical benefit is greatest in permissive tumor microenvironments. Responders exhibit enrichment of cytotoxic T cells across tumor and stromal compartments, whereas non-responders display heterogeneous cellular neighborhoods, with fibroblasts in close spatial proximity to T cells, consistent with barriers to immune-mediated clearance. Longitudinal peripheral immune profiling shows that early upregulation of TIGIT and PD-1 following TMZ exposure predicts resistance. Together, these findings indicate that both mutational evolution and spatial immune architecture contribute to immune sensitization in MGMT-silenced MSS CRC. Clinical Trial Identification: NCT03832621.